

APPENDIX A

1. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of: first molecules directed against CD3, and second molecules, distinct from said first molecules, said second molecules directed against CD7, wherein at least one of said first and said second molecules include a toxic moiety.
2. The method according to claim 15, wherein said second molecules specifically recognize CD7.
3. The pharmaceutical composition of claim 1, wherein said first molecules are antibodies.
4. The pharmaceutical composition of claim 1, wherein said second molecules are antibodies.
5. The pharmaceutical composition of claim 1, wherein said toxic moiety is ricin.
6. The pharmaceutical composition of claim 5, wherein said ricin is deglycosylated ricin A.
7. The pharmaceutical composition of claim 1, wherein said toxic moiety is chemically linked to said first and/or second molecules.
8. The pharmaceutical composition of claim 1, wherein said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
10. The pharmaceutical composition of claim 1, wherein said first molecules are gamma2B IgG.
11. The pharmaceutical composition of claim 5, wherein the toxic moiety is at least the equivalent dose of 25 micrograms of ricin A per square meter of body surface of a subject to which the composition is to be administered.
12. The pharmaceutical composition of claim 11, wherein the toxic moiety is at least the equivalent dose of 100 micrograms of ricin A per square meter of the subject's body surface per administration.
13. The pharmaceutical composition of claim 11, wherein the toxic moiety is at most the equivalent dose of 25 mg of ricin A per square meter of the subject's body surface per infusion.
15. A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune disease, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of: first molecules directed against a CD3

positive cell, and second molecules, distinct from said first molecules, directed against a CD7 positive cell, wherein at least the second molecules include a toxic moiety.

18. The pharmaceutical composition of claim 2, wherein said first molecules are antibodies.
19. The pharmaceutical composition of claim 18, wherein said second molecules are antibodies.
20. The pharmaceutical composition of claim 19, wherein said toxic moiety is deglycosylated ricin A.
21. The pharmaceutical composition of claim 19, wherein said toxic moiety is chemically linked to said first and second molecules.
22. The pharmaceutical composition of claim 21, wherein both said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
23. The pharmaceutical composition of claim 18, wherein said first molecules are gamma2B IgG.
24. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of: anti-CD3 antibodies; and anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
25. A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune diseases, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of: anti-CD3 antibodies; and anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
26. The composition of claim 1, wherein said second molecules include a toxic moiety.

THE PATENT & TRADEMARK OFFICE MAILROOM DATE
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Brief on Appeal (16 pages); Petition for Extension of Time (1 page);
Check no. 5606 in the amount of \$210.00

Invention: METHODS AND MEANS FOR THE TREATMENT
OF IMMUNE RELATED DISEASES
Applicant(s): van Oosterhout et al.
Filing Date: September 22, 2000
Serial No.: 09/668,555
Date Sent: January 14, 2004 via Express Mail Label No.
Docket No.: EL994821789US
ACT/sdd



RECEIVED
JAN 26 2004
TRASKBRITT, P.C.



TRASKBRITT
P.O. Box 2550
Salt Lake City, UT 84110-2550

RECEIVED
JAN 26 2004
TRASKBRITT, P.C.

08/09/2004 13:57 8015319168

WARNING THIS DOCUMENT HAS FLUORESCENT FIBERS.

TRASKBRITT

PAGE 20/24

TRASK BRITT, P.
PATENT ATTORNEYS, CLIENT ADVANCE ACCOUNT
230 SOUTH 500 EAST, SUITE 300
P.O. BOX 2550
SALT LAKE CITY, UT 84102
PHONE: 801-532-1922

KEY BANK OF UTAH
SALT LAKE CITY, UT

31-78-1240

DATE 01/14/2004

560

PAY
EXACTLY Two Hundred Ten AND 00/100 DOLLARS

\$ 210.00

TO THE
ORDER OF
Commissioner for Patents

Washington, D.C. 20231

MP
AUTHORIZED SIGNATURE

100056061017480073714450400100161

1000021000



PROCESSED BY FBI-SAC-ATLANTA
MAY 20 1968
FBI-CLEVELAND
PAYOR BANK

SEARCHED INDEXED SERIALIZED FILED
MARCH NINETEEN EIGHTY-THREE BY
CITY OF PHILADELPHIA PA 9122882

10-280

ب

YOUR ENDORSEMENT IN THE ABOVE AREA ONLY
DO NOT SIGN. WRITE ON STAMP BELOW THIS LINE

FOR DEPOSITORY BANK USE ONLY

卷之三

ארכיאולוגיה עתיקה



Mailing Label
Label T7-F June 2002



UNITED STATES POSTAL SERVICE®

Post Office To Addressee

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery	Flat Rate Envelope
	<input type="checkbox"/> Next <input type="checkbox"/> Second <input type="checkbox"/>	
Date In	Postage	
Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	\$
Time In	Military Return Receipt Fee	
<input type="checkbox"/> AM <input type="checkbox"/> PM	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	
Weight	Intl Alpha Country Code	COD Fee Insurance Fee
Ibs. OZs.		
No Delivery	Acceptance Clerk Initials	Total Postage & Fees
<input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		\$

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Date	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	

W A R N I N G O F S I G N A T U R E (Domestic Only) Additional charges will be imposed if hold or return of package is requested. Authorization to be made without delivery is granted to addressee or addressee's agent if delivery employee judges that article can be left in secure location and return receipt is given. Authorization is granted to addressee or addressee's agent to accept delivery of package if delivery employee judges that article can be left in secure location and return receipt is given. Consumer signatures are required for delivery.

NO DELIVERY Workday Holiday Saturday Sunday Consumer Signature

CUSTOMER USE ONLY

METHOD OF PAYMENT:

Express Mail Corporate Acct. No. X841812

Federal Agency Acct. No. or
Postal Service Acct. No.

FROM: (PLEASE PRINT) 801 532 1922

TO: (PLEASE PRINT) PHONE

TRASK BRITT LAW OFFICE
230 S 500 E STE 300
SALT LAKE CITY UT 84102-2000

MAIL STOP APPEAL BRIEF - PATENTS
COMMISSIONER FOR PATENTS
US PATENTS OFFICE
PO BOX 1450
ALEXANDRIA VA 22313-1450

PRESS HARD.
You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com



THE PATENT & TRADEMARK OFFICE MAILROOM DATE
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Brief on Appeal (16 pages); Petition for Extension of Time (1 page);
Check no. 5606 in the amount of \$210.00

Invention: METHODS AND MEANS FOR THE TREATMENT
OF IMMUNE RELATED DISEASES
Applicant(s): van Oosterhout et al.
Filing Date: September 22, 2000
Serial No.: 09/668,555
Date Sent: January 14, 2004 via Express Mail Label No.
Docket No.: EL994821789US
ACT/sdd 2183-4541US

560

TRASK BRITT, P.C. PATENT ATTORNEYS / CLIENT ADVANCE ACCOUNT

SD

DATE	INVOICE #	REFERENCE	AMOUNT
01/14/2004		Extension for Response Within Second Mon 2183-4541US	210.00
			210.00

WARNING THIS DOCUMENT HAS FLUORESCENT FIBERS, A VOID PANTOGRAPH AND A MICROPRINT SIGNATURE LINE 

560

TRASK BRITT, P.C.

PATENT ATTORNEYS / CLIENT ADVANCE ACCOUNT

230 SOUTH 500 EAST, SUITE 300

P.O. BOX 2550

SALT LAKE CITY, UT 84102

PHONE: 801-532-1922


KEY BANK OF UTAH
SALT LAKE CITY, UT

33-7341240

DATE 01/14/2004

PAY EXACTLY Two Hundred Ten AND 00/100 DOLLARS

\$ 210.00

TO THE
Commissioner for Patents
Washington, D.C. 20231

AUTHORIZED SIGNATURE

NP

1005606117124000737445010030416